Document Detail


Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.
MedLine Citation:
PMID:  20359629     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Laboratory evidence and clinical evidence suggest that some patients with myelodysplastic syndrome (MDS) have immunologically mediated disease. This article describes the laboratory evidence supporting a role for the immune system in the marrow failure of MDS and clinical trials using IST in these patients.
Authors:
Elaine M Sloand; A J Barrett
Related Documents :
20054529 - Infantile form of scimitar syndrome with contralateral pulmonary vein stenosis.
21770779 - Screening for retinal vessel caliber and its association with metabolic syndrome in jap...
12446199 - Response to erythropoietin and moxifloxacin in a patient with myelodysplastic syndrome ...
18239739 - Not just any icd device in patients with long-qt syndrome.
7993249 - Shoulder impingement syndrome: diagnostic accuracy of magnetic resonance imaging and ra...
9425479 - Cochlear implantation in patients suffering from cogan's syndrome.
20327419 - Autosomal trisomies and partial trisomy syndromes: (with presentation of two cases of p...
8469589 - Smith-lemli-opitz syndrome type ii: report of a case with additional radiographic findi...
7243439 - The velo-cardio-facial syndrome: a clinical and genetic analysis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  24     ISSN:  1558-1977     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-02     Completed Date:  2010-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  331-41     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Inc.
Affiliation:
Hematology Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, 10 Center Drive, Bethesda, MD 20892, USA. sloande@nhlbi.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antilymphocyte Serum / therapeutic use
Apoptosis
Biomedical Research
Bone Marrow / pathology
Clinical Medicine
Clinical Trials as Topic / statistics & numerical data
Cyclosporine / therapeutic use
Cytokines / secretion
Female
Humans
Immunosuppression*
Immunosuppressive Agents / therapeutic use*
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*,  immunology,  pathology
T-Lymphocytes / immunology
Tumor Necrosis Factor-alpha / antagonists & inhibitors,  physiology
Chemical
Reg. No./Substance:
0/Antilymphocyte Serum; 0/Cytokines; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epigenetic changes in the myelodysplastic syndrome.
Next Document:  Innate Immune Signaling in the Myelodysplastic Syndromes.